Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan

Toshihiko Taguchi, Ataru Igarashi, Stephen Watt, Bruce Parsons, Alesia Sadosky, Kazutaka Nozawa, Kazuhiro Hayakawa, Tamotsu Yoshiyama, Nozomi Ebata, Koichi Fujii, Toshihiko Taguchi, Ataru Igarashi, Stephen Watt, Bruce Parsons, Alesia Sadosky, Kazutaka Nozawa, Kazuhiro Hayakawa, Tamotsu Yoshiyama, Nozomi Ebata, Koichi Fujii

Abstract

Objective: To evaluate the impact of pregabalin on sleep, pain, function, and health status in patients with chronic low back pain with accompanying neuropathic pain (CLBP-NeP) under routine clinical practice.

Methods: This prospective, non-interventional, observational study enrolled Japanese adults (≥18 years) with CLBP-NeP of duration ≥3 months and severity ≥5 on a numerical rating scale (0= no pain, 10= worst possible pain). Treatment was 8 weeks with pregabalin (n=157) or usual care alone (n=174); choice of treatment was determined by the physician. The primary efficacy outcome was change from baseline to 8 weeks in pain-related interference with sleep, assessed using the Pain-Related Sleep Interference Scale (PRSIS; 0= did not interfere with sleep, 10= completely interferes with sleep). Secondary endpoints were changes in PRSIS at week 4, and changes at weeks 4 and 8 in pain (numerical rating scale), function (Roland-Morris Disability Questionnaire), and quality of life (EuroQol 5D-5L); global assessments of change were evaluated from the clinician and patient perspectives at the final visit.

Results: Demographic characteristics were similar between cohorts, but clinical characteristics suggested greater disease severity in the pregabalin group including a higher mean (standard deviation) pain score, 6.3 (1.2) versus 5.8 (1.1) (P<0.001). For the primary endpoint, pregabalin resulted in significantly greater improvements in PRSIS at week 8, least-squares mean changes of -1.3 versus -0.4 for usual care (P<0.001); pregabalin also resulted in greater PRSIS improvement at week 4 (P=0.012). Relative to usual care at week 8, pregabalin improved pain and function (both P<0.001), and showed global improvements since beginning study medication (P<0.001). Pregabalin was well tolerated.

Conclusion: In clinical practice in patients with CLBP-NeP, pregabalin showed significantly greater improvements in pain-related interference with sleep relative to usual care. In addition, pregabalin significantly improved pain, function, and health status, suggesting the benefits of pregabalin for overall health and well-being relative to usual care in these patients. (Clinicaltrials. gov identifier NCT02273908).

Keywords: chronic low back pain; neuropathic pain; non-interventional study; pregabalin; sleep; usual care.

Figures

Figure 1
Figure 1
Patient disposition. Notes:*Choice of therapy determined by the clinical judgment of the treating physician; #the full analysis set consisted of subjects who had at least one evaluable observation from any of the patient-reported outcomes, and only evaluable subjects who contributed to the particular outcome were evaluated in each analysis.
Figure 2
Figure 2
Change from baseline in sleep disturbance, assessed using the Pain-Related sleep interference scale (PRSIS). Note:*P<0.05 versus usual care. Abbreviation: LS, least-squares.
Figure 3
Figure 3
Efficacy of treatment for pain assessed using a pain numerical rating scale (NRS). Notes: (A) Change from baseline. (B) Proportions of patients at week 8 (last observation carried forward) reporting clinically relevant improvements in pain. *P<0.05 versus usual care. Abbreviation: LS, least-squares.
Figure 4
Figure 4
Change from baseline in function, assessed by the Roland-Morris Disability Questionnaire (RMDQ). Note:*P<0.05 versus usual care. Abbreviation: LS, least-squares.
Figure 5
Figure 5
Global impression of change at week 8 from the perspectives of (A) the clinician, assessed using the Clinician Global Impression of Change (CGI-C), and (B) the patient, assessed using the Patient Global Impression of Change (PGI-C). Notes: Categories are collapsed into “Improved”, consisting of “minimally improved”, “much improved”, and “very much improved”, and “Worsened”, consisting of “minimally worse”, “much worse”, and “very much worse”. Differences between pregabalin and usual care were significant for the full set of categories on the CGI-C and PGI-C (both P<0.05).

References

    1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196.
    1. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 2008;8(1):8–20.
    1. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290(18):2443–2454.
    1. Fujii T, Matsudaira K. Prevalence of low back pain and factors associated with chronic disabling back pain in Japan. Eur Spine J. 2013;22(2):432–438.
    1. Suka M, Yoshida K. Low back pain deprives the Japanese adult population of their quality of life: a questionnaire survey at five healthcare facilities in Japan. Environ Health Prev Med. 2008;13(2):109–115.
    1. Sadosky AB, DiBonaventura M, Cappelleri JC, Ebata N, Fujii K. The association between lower back pain and health status, work productivity, and health care resource use in Japan. J Pain Res. 2015;8:119–130.
    1. Becker A, Held H, Redaelli M, et al. Low back pain in primary care. Costs of care and prediction of future health care utilization. Spine (Phila Pa 1976) 2010;35(18):1714–1720.
    1. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep. 2009;13(3):185–190.
    1. Giesecke T, Gracely RH, Grant MA, et al. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum. 2004;50(2):613–623.
    1. Dionne CE, Dunn KM, Croft PR, et al. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine (Phila Pa 1976) 2008;33(1):95–103.
    1. Webb R, Brammah T, Lunt M, Urwin M, Allison T, Symmons D. Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. Spine (Phila Pa 1976) 2003;28(11):1195–1202.
    1. Yamashita T, Takahashi K, Yonenobu K, Kikuchi S. Prevalence of neuropathic pain in cases with chronic pain related to spinal disorders. J Orthop Sci. 2014;19(1):15–21.
    1. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911–1920.
    1. Fishbain DA, Cole B, Lewis JE, Gao J. What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med. 2014;15(1):4–15.
    1. Ogawa S, Komatsu M, Ohno S, Yamane H, Hayakawa K. Interim report of drug use investigations of pregabalin (Lyrica) Progress in Medicine. 2013;33(10):2159–2171. Japanese.
    1. McCracken LM, Iverson GL. Disrupted sleep patterns and daily functioning in patients with chronic pain. Pain Res Manag. 2002;7(2):75–79.
    1. Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004;8(2):119–132.
    1. Kundermann B, Lautenbacher S. Effects of impaired sleep quality and sleep deprivation on diurnal pain perception. In: Lavigne G, Sessle B, Choiniere M, Soja P, editors. Sleep and Pain. Seattle: IASP Press; 2007. pp. 137–152.
    1. Kelly GA, Blake C, Power CK, O’Keeffe D, Fullen BM. The association between chronic low back pain and sleep: a systematic review. Clin J Pain. 2011;27(2):169–181.
    1. Marin R, Cyhan T, Miklos W. Sleep disturbance in patients with chronic low back pain. Am J Phys Med Rehabil. 2006;85(5):430–435.
    1. Marty M, Rozenberg S, Duplan B, et al. Quality of sleep in patients with chronic low back pain: a case-control study. Eur Spine J. 2008;17(6):839–844.
    1. Mann R, Bergstrom F, Schaefer C, et al. Burden of spinal cord injury-related neuropathic pain in the United States: retrospective chart review and cross-sectional survey. Spinal Cord. 2013;51(7):564–570.
    1. Langley PC, Van Litsenburg C, Cappelleri JC, Carroll D. The burden associated with neuropathic pain in Western Europe. J Med Econ. 2013;16(1):85–95.
    1. Sadosky A, Schaefer C, Mann R, et al. Burden of chronic low back pain with a neuropathic pain component: retrospective chart review and cross-sectional survey among adults seeking treatment in the United States. J Pain Relief. 2014;3:163.
    1. Roland M, Morris R. A study of the natural history of back pain. Part I: Development of a reliable and sensitive measure of disability in low back pain. Spine (Phila Pa 1976) 1983;8(2):141–144.
    1. The Japanese Orthopaedic Association . The practice guideline for low back pain 2012. Nankodo Co, Ltd: Tokyo, Japan; [Accessed July 7, 2015]. Available from: . Japanese.
    1. National Institute for Health and Clinical Excellence [homepage on the Internet] Neuropathic pain – pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings. NICE; 2013. [Accessed April 27, 2015]. Available from: .
    1. Koes BW, van Tulder M, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010;19(12):2075–2094.
    1. Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–S14.
    1. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006;103(46):17537–17542.
    1. Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28(1):109–116.
    1. Ogawa S, Suzuki M, Arakawa A, et al. Evaluation of the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia: a randomized, double-blind, multicenter, placebo-controlled study. J Japan Soc Pain Clin. 2010;17(2):141–152. Japanese.
    1. Cardenas DD, Nieshoff EC, Suda K, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. 2013;80(6):533–539.
    1. Ogawa S, Satoh J, Arakawa A, Yoshiyama T, Suzuki M. Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. Drug Saf. 2012;35(10):793–806.
    1. Roth T, Arnold LM, Garcia-Borreguero D, Resnick M, Clair AG. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Med Rev. 2014;18(3):261–271.
    1. Toelle T, Varvara R, Nimour M, Emir B, Brasser M. Pregabalin in neuropathic pain related to DPN, cancer and back pain: analysis of a 6-week observational study. Open Pain J. 2012;5:1–11.
    1. Saldana MT, Navarro A, Perez C, Masramon X, Rejas J. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol Int. 2010;30(8):1005–1015.
    1. Goren A, Mould-Quevedo J, daCosta DiBonaventura M. Prevalence of pain reporting and associated health outcomes across emerging markets and developed countries. Pain Med. 2014;15(11):1880–1891.
    1. Turk DC, Dworkin RH, Revicki D, et al. Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain. 2008;137(2):276–285.
    1. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106(3):337–345.
    1. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19.
    1. Haanpaa M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152(1):14–27.
    1. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS Score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6(3):149–158.
    1. Smith MT, Edwards RR, McCann UD, Haythornthwaite JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep. 2007;30(4):494–505.
    1. Smith MT, Perlis ML, Smith MS, Giles DE, Carmody TP. Sleep quality and presleep arousal in chronic pain. J Behav Med. 2000;23(1):1–13.
    1. Morin CM, Gibson D, Wade J. Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain. 1998;14(4):311–314.
    1. Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain. 2014;14(12):1539–1552.
    1. Sezgin M, Hasanefendioglu EZ, Ali Sungur M, et al. Sleep quality in patients with chronic low back pain: A cross-sectional study assesing its relations with pain, functional status and quality of life. J Back Musculoskelet Rehabil. 2014 Oct 15; Epub.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.
    1. Vernon MK, Brandenburg NA, Alvir JM, Griesing T, Revicki DA. Reliability, validity, and responsiveness of the daily sleep interference scale among diabetic peripheral neuropathy and postherpetic neuralgia patients. J Pain Symptom Manage. 2008;36(1):54–68.
    1. Anastassiou E, Iatrou CA, Vlaikidis N, et al. Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig. 2011;31(6):417–426.
    1. Parsons B, Emir B, Knapp L. Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. Am J Ther. 2014 Sep 30; Epub.
    1. Ostelo RW, de Vet HC. Clinically important outcomes in low back pain. Best Pract Res Clin Rheumatol. 2005;19(4):593–607.
    1. Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain. Towards international consensus regarding minimal important change. Spine (Phila Pa 1 976) 2008;33(1):90–94.
    1. Jordan K, Dunn KM, Lewis M, Croft P. A minimal clinically important difference was derived for the Roland-Morris Disability Questionnaire for low back pain. J Clin Epidemiol. 2006;59(1):42–52.
    1. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–121.
    1. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727–1736.
    1. Guy W. ECDEU assessment manual for psychopharmacology, revised US Department of Health, Education, and Welfare publication (ADM) Rockville, MD: National Institute of Mental Health; 1976.
    1. Ikeda S, Shiroiwa T, Igarashi A, et al. Developing a Japanese version of the EQ-5D-5L value set. J Natl Inst Public Health. 2015;64(1):47–55. Japanese.
    1. Suzukamo Y, Fukuhara S, Kikuchi S, et al. Validation of the Japanese version of the Roland-Morris Disability Questionnaire. J Orthop Sci. 2003;8(4):543–548.
    1. Morera-Dominguez C, Ceberio-Balda F, Florez-Garcia M, Masramon X, Lopez-Gomez V. A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics. Clin Drug Investig. 2010;30(8):517–531.
    1. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J. 2008;42(4):303–319.
    1. Markman JD, Frazer ME, Rast SA, et al. Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. Neurology. 2015;84(3):265–272.
    1. Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain. 1996;68(2–3):363–368.
    1. Edwards RR, Almeida DM, Klick B, Haythornthwaite JA, Smith MT. Duration of sleep contributes to next-day pain report in the general population. Pain. 2008;137(1):202–207.
    1. Roth T, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin. 2010;26(10):2411–9241.
    1. Vinik A, Emir B, Parsons B, Cheung R. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia. Pain Med. 2014;15(4):661–670.
    1. Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013;35(5):612–623.
    1. Onouchi K, Koga H, Yokoyama K, Yoshiyama T. An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. J Pain Res. 2014;7:439–447.
    1. Joshi AB, Gill GS, Smith PL. Outcome in patients lost to follow-up. J Arthroplasty. 2003;18(2):149–153.
    1. Poon KH, Yeo S, Tong L. Lost to follow-up for appointments in a dedicated dry eye clinic. Patient Prefer Adherence. 2014;8:1409–1418.
    1. Han JJ, Lee JH, Oh SH, Chang SO, Suh MW. Assessing the Effects of Tinnitus Retraining Therapy in Patients Lost to Follow-up: A Telephone Survey. Otol Neurotol. 2015;36(4):581–587.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner